501 related articles for article (PubMed ID: 28108885)
1. Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials.
Ellingson BM; Wen PY; Cloughesy TF
Neurotherapeutics; 2017 Apr; 14(2):307-320. PubMed ID: 28108885
[TBL] [Abstract][Full Text] [Related]
2. Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma.
Tensaouti F; Khalifa J; Lusque A; Plas B; Lotterie JA; Berry I; Laprie A; Cohen-Jonathan Moyal E; Lubrano V
Neuroradiology; 2017 Oct; 59(10):1013-1020. PubMed ID: 28842741
[TBL] [Abstract][Full Text] [Related]
3. Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.
Strauss SB; Meng A; Ebani EJ; Chiang GC
Neuroimaging Clin N Am; 2021 Feb; 31(1):103-120. PubMed ID: 33220823
[TBL] [Abstract][Full Text] [Related]
4. Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis.
Delgado-López PD; Riñones-Mena E; Corrales-García EM
Clin Transl Oncol; 2018 Aug; 20(8):939-953. PubMed ID: 29218626
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the apparent diffusion coefficient in patients with recurrent glioblastoma under treatment with bevacizumab with radiographic pseudoresponse.
Auer TA; Breit HC; Marini F; Renovanz M; Ringel F; Sommer CJ; Brockmann MA; Tanyildizi Y
J Neuroradiol; 2019 Feb; 46(1):36-43. PubMed ID: 29733920
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.
Wick W; Chinot OL; Bendszus M; Mason W; Henriksson R; Saran F; Nishikawa R; Revil C; Kerloeguen Y; Cloughesy T
Neuro Oncol; 2016 Oct; 18(10):1434-41. PubMed ID: 27515827
[TBL] [Abstract][Full Text] [Related]
7. Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma.
Qin L; Li X; Stroiney A; Qu J; Helgager J; Reardon DA; Young GS
Neuroradiology; 2017 Feb; 59(2):135-145. PubMed ID: 28070598
[TBL] [Abstract][Full Text] [Related]
8. Small increases in enhancement on MRI may predict survival post radiotherapy in patients with glioblastoma.
Gzell CE; Wheeler HR; McCloud P; Kastelan M; Back M
J Neurooncol; 2016 May; 128(1):67-74. PubMed ID: 26879084
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question.
Nasseri M; Gahramanov S; Netto JP; Fu R; Muldoon LL; Varallyay C; Hamilton BE; Neuwelt EA
Neuro Oncol; 2014 Aug; 16(8):1146-54. PubMed ID: 24523362
[TBL] [Abstract][Full Text] [Related]
10. Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.
Strauss SB; Meng A; Ebani EJ; Chiang GC
Radiol Clin North Am; 2019 Nov; 57(6):1199-1216. PubMed ID: 31582045
[TBL] [Abstract][Full Text] [Related]
11. Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas.
Moon HH; Kim HS; Park JE; Kim YH; Kim JH
BMC Cancer; 2021 Jun; 21(1):654. PubMed ID: 34074252
[TBL] [Abstract][Full Text] [Related]
12. Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.
Gahrmann R; van den Bent M; van der Holt B; Vernhout RM; Taal W; Vos M; de Groot JC; Beerepoot LV; Buter J; Flach ZH; Hanse M; Jasperse B; Smits M
Neuro Oncol; 2017 Jun; 19(6):853-861. PubMed ID: 28204639
[TBL] [Abstract][Full Text] [Related]
13. Differentiation of Pseudoprogression from True Progressionin Glioblastoma Patients after Standard Treatment: A Machine Learning Strategy Combinedwith Radiomics Features from T
Sun YZ; Yan LF; Han Y; Nan HY; Xiao G; Tian Q; Pu WH; Li ZY; Wei XC; Wang W; Cui GB
BMC Med Imaging; 2021 Feb; 21(1):17. PubMed ID: 33535988
[TBL] [Abstract][Full Text] [Related]
14. Imaging of the Posttherapeutic Brain.
Telles BA; D'Amore F; Lerner A; Law M; Shiroishi MS
Top Magn Reson Imaging; 2015 Jun; 24(3):147-54. PubMed ID: 26049818
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent Glioblastoma.
Youssef G; Rahman R; Bay C; Wang W; Lim-Fat MJ; Arnaout O; Bi WL; Cagney DN; Chang YS; Cloughesy TF; DeSalvo M; Ellingson BM; Flood TF; Gerstner ER; Gonzalez Castro LN; Guenette JP; Kim AE; Lee EQ; McFaline-Figueroa JR; Potter CA; Reardon DA; Huang RY; Wen PY
J Clin Oncol; 2023 Jun; 41(17):3160-3171. PubMed ID: 37027809
[TBL] [Abstract][Full Text] [Related]
16. Differentiating pseudoprogression from true progression: analysis of radiographic, biologic, and clinical clues in GBM.
Rowe LS; Butman JA; Mackey M; Shih JH; Cooley-Zgela T; Ning H; Gilbert MR; Smart DK; Camphausen K; Krauze AV
J Neurooncol; 2018 Aug; 139(1):145-152. PubMed ID: 29767308
[TBL] [Abstract][Full Text] [Related]
17. Quantitative T1-mapping detects cloudy-enhancing tumor compartments predicting outcome of patients with glioblastoma.
Müller A; Jurcoane A; Kebir S; Ditter P; Schrader F; Herrlinger U; Tzaridis T; Mädler B; Schild HH; Glas M; Hattingen E
Cancer Med; 2017 Jan; 6(1):89-99. PubMed ID: 27891815
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility and Tumor Size Changes During the Time Course of Standard Treatment in Recurrent Glioblastoma.
van Leyen K; Roelcke U; Gruber P; Remonda L; Berberat J
J Neuroimaging; 2019 Sep; 29(5):645-649. PubMed ID: 31112344
[TBL] [Abstract][Full Text] [Related]
19. Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study.
Kickingereder P; Isensee F; Tursunova I; Petersen J; Neuberger U; Bonekamp D; Brugnara G; Schell M; Kessler T; Foltyn M; Harting I; Sahm F; Prager M; Nowosielski M; Wick A; Nolden M; Radbruch A; Debus J; Schlemmer HP; Heiland S; Platten M; von Deimling A; van den Bent MJ; Gorlia T; Wick W; Bendszus M; Maier-Hein KH
Lancet Oncol; 2019 May; 20(5):728-740. PubMed ID: 30952559
[TBL] [Abstract][Full Text] [Related]
20. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
